Handelen GlaxoSmithKline PLC - GSKl CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.040 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.028007% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.015829% | ||||||||
| Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 0.1 | ||||||||
| Valuta | GBP | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
GSK plc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 14.31 |
| Open* | 14.205 |
| 1-Jaarlijkse Verandering* | -13.88% |
| Dagelijks bereik* | 14.165 - 14.445 |
| 52 wekelijks bereik | 12.81-18.43 |
| Weekgemiddelde volume (10 dagen) | 12.94M |
| Gemiddeld volume (3 maanden) | 176.48M |
| Marktkapitalisatie | 58.95B |
| P/E Ratio | 13.18 |
| Uitstaande Aandelen | 4.09B |
| Omzet | 29.32B |
| EPS | 1.09 |
| Dividend (opbrengst %) | 6.25174 |
| Beta | 0.57 |
| Volgende inkomsten datum | Apr 26, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Feb 2, 2023 | 14.310 | 0.080 | 0.56% | 14.230 | 14.355 | 14.055 |
| Feb 1, 2023 | 14.190 | -0.130 | -0.91% | 14.320 | 14.430 | 14.030 |
| Jan 31, 2023 | 14.270 | 0.145 | 1.03% | 14.125 | 14.330 | 14.055 |
| Jan 30, 2023 | 14.130 | 0.145 | 1.04% | 13.985 | 14.260 | 13.985 |
| Jan 27, 2023 | 14.100 | 0.065 | 0.46% | 14.035 | 14.215 | 14.035 |
| Jan 26, 2023 | 14.025 | 0.040 | 0.29% | 13.985 | 14.140 | 13.980 |
| Jan 25, 2023 | 13.995 | 0.040 | 0.29% | 13.955 | 14.040 | 13.920 |
| Jan 24, 2023 | 13.930 | -0.150 | -1.07% | 14.080 | 14.125 | 13.835 |
| Jan 23, 2023 | 14.120 | 0.075 | 0.53% | 14.045 | 14.170 | 14.040 |
| Jan 20, 2023 | 14.035 | -0.160 | -1.13% | 14.195 | 14.195 | 14.005 |
| Jan 19, 2023 | 14.165 | 0.095 | 0.68% | 14.070 | 14.215 | 14.025 |
| Jan 18, 2023 | 14.130 | -0.155 | -1.09% | 14.285 | 14.290 | 14.015 |
| Jan 17, 2023 | 14.375 | 0.010 | 0.07% | 14.365 | 14.400 | 14.275 |
| Jan 16, 2023 | 14.375 | 0.150 | 1.05% | 14.225 | 14.400 | 14.225 |
| Jan 13, 2023 | 14.365 | 0.270 | 1.92% | 14.095 | 14.415 | 14.095 |
| Jan 12, 2023 | 14.325 | 0.205 | 1.45% | 14.120 | 14.330 | 14.090 |
| Jan 11, 2023 | 14.095 | 0.010 | 0.07% | 14.085 | 14.245 | 14.065 |
| Jan 10, 2023 | 14.110 | 0.115 | 0.82% | 13.995 | 14.195 | 13.995 |
| Jan 9, 2023 | 14.220 | -0.085 | -0.59% | 14.305 | 14.320 | 14.100 |
| Jan 6, 2023 | 14.285 | 0.095 | 0.67% | 14.190 | 14.390 | 14.165 |
GlaxoSmithKline PLC Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale inkomsten | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
| Inkomsten | 27889 | 30186 | 30821 | 33754 | 34099 | 34114 |
| Kosten van opbrengsten, totaal | 8898 | 9317 | 9572 | 10168 | 10890 | 11427 |
| Brutowinst | 18991 | 20869 | 21249 | 23586 | 23209 | 22687 |
| Totale bedrijfskosten | 25291 | 26005 | 25335 | 26793 | 26316 | 27949 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 8859 | 9341 | 9408 | 10671 | 10717 | 10225 |
| Onderzoek & Ontwikkeling | 3468 | 3862 | 3726 | 4338 | 4603 | 4776 |
| Depreciation / Amortization | 41 | 45 | 44 | 64 | 76 | 101 |
| Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | 3664 | 2139 | 1839 | -128 | 1220 | 1073 |
| Ongebruikelijke uitgaven (inkomsten) | 782 | 1666 | 1038 | 2051 | -807 | 772 |
| Other Operating Expenses, Total | -421 | -365 | -292 | -371 | -383 | -425 |
| Bedrijfsresultaat | 2598 | 4181 | 5486 | 6961 | 7783 | 6165 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -628 | -646 | -602 | -708 | -432 | -1317 |
| Overige, Netto | -31 | -10 | -84 | -32 | -383 | 594 |
| Netto inkomen voor belastingen | 1939 | 3525 | 4800 | 6221 | 6968 | 5442 |
| Netto inkomen na belastingen | 1062 | 3247 | 3921 | 5268 | 6388 | 5096 |
| Minderheidsbelang | -150 | -637 | -423 | -623 | -639 | -711 |
| Netto inkomen voor extra. Posten | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
| Netto inkomen | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 912 | 2610 | 3498 | 4645 | 5749 | 4385 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 912 | 1532 | 3623 | 4645 | 5749 | 4385 |
| Verwateringsaanpassing | 1.074 | 0 | ||||
| Verwaterd Netto Inkomen | 913.074 | 1532 | 3623 | 4645 | 5749 | 4385 |
| Verwaterd Gewogen Gemiddelde Aandelen | 4909 | 4941 | 4971 | 5016 | 5038 | 5065 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.186 | 0.52823 | 0.70368 | 0.92604 | 1.14113 | 0.86575 |
| Dividends per Share - Common Stock Primary Issue | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| Verwaterde Genormaliseerde Winst per Aandeel | 0.32758 | 0.94697 | 0.85456 | 1.35566 | 0.9736 | 0.87285 |
| Totale buitengewone posten | -1078 | 125 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 7418 | 8092 | 9077 | 9527 | 9780 |
| Inkomsten | 7418 | 8092 | 9077 | 9527 | 9780 |
| Kosten van opbrengsten, totaal | 2411 | 2519 | 2822 | 3675 | 3645 |
| Brutowinst | 5007 | 5573 | 6255 | 5852 | 6135 |
| Totale bedrijfskosten | 5725 | 6453 | 7139 | 8632 | 6979 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 2315 | 2498 | 2504 | 2908 | 2681 |
| Onderzoek & Ontwikkeling | 1077 | 1165 | 1169 | 1363 | 1154 |
| Depreciation / Amortization | 26 | 25 | 25 | 25 | 23 |
| Ongebruikelijke uitgaven (inkomsten) | -13 | 323 | 735 | 796 | -385 |
| Other Operating Expenses, Total | -91 | -77 | -116 | -135 | -139 |
| Bedrijfsresultaat | 1693 | 1639 | 1938 | 895 | 2801 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -175 | -169 | -190 | -189 | -203 |
| Netto inkomen voor belastingen | 1518 | 1470 | 1748 | 706 | 2598 |
| Netto inkomen na belastingen | 1260 | 1538 | 1368 | 930 | 2167 |
| Minderheidsbelang | -187 | -143 | -200 | -181 | -365 |
| Netto inkomen voor extra. Posten | 1073 | 1395 | 1168 | 749 | 1802 |
| Netto inkomen | 1073 | 1395 | 1168 | 749 | 1802 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 1073 | 1395 | 1168 | 749 | 1802 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 1073 | 1395 | 1168 | 749 | 1802 |
| Verwateringsaanpassing | 0 | ||||
| Verwaterd Netto Inkomen | 1073 | 1395 | 1168 | 749 | 1802 |
| Verwaterd Gewogen Gemiddelde Aandelen | 5037 | 5060 | 5060 | 5074 | 5068 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.21302 | 0.27569 | 0.23083 | 0.14762 | 0.35556 |
| Dividends per Share - Common Stock Primary Issue | 0.19 | 0.19 | 0.19 | 0.23 | 0.14 |
| Verwaterde Genormaliseerde Winst per Aandeel | 0.19873 | 0.25375 | 0.3419 | 0.22566 | 0.2717 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totaal vlottende activa | 16711 | 15907 | 16927 | 19491 | 20247 | 18674 |
| Geldmiddelen en kortetermijnbeleggingen | 4986 | 3911 | 3958 | 4786 | 6370 | 4335 |
| Cash | 1462 | 826 | 569 | 795 | 1762 | 1427 |
| Korte Termijn Investeringen | 3524 | 3085 | 3389 | 3991 | 4608 | 2908 |
| Totale Vorderingen, Netto | 5917 | 5950 | 6322 | 7148 | 7264 | 8031 |
| Accounts Receivable - Trade, Net | 4679 | 4693 | 5185 | 5494 | 5562 | 6258 |
| Total Inventory | 5102 | 5557 | 5476 | 5947 | 5996 | 5783 |
| Prepaid Expenses | 335 | 308 | 330 | 316 | 359 | 315 |
| Other Current Assets, Total | 371 | 181 | 841 | 1294 | 258 | 210 |
| Total Assets | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
| Property/Plant/Equipment, Total - Net | 10808 | 10860 | 11058 | 11314 | 11006 | 10672 |
| Property/Plant/Equipment, Total - Gross | 22164 | 21719 | 22488 | 22565 | 22313 | 21518 |
| Accumulated Depreciation, Total | -11356 | -10859 | -11430 | -11251 | -11307 | -10846 |
| Goodwill, Net | 5965 | 5734 | 5789 | 10562 | 10597 | 10552 |
| Intangibles, Net | 18776 | 17562 | 17202 | 30955 | 29824 | 30079 |
| Long Term Investments | 1248 | 1101 | 1558 | 2151 | 3424 | 2214 |
| Note Receivable - Long Term | 886 | 875 | 816 | 893 | 858 | 935 |
| Other Long Term Assets, Total | 4687 | 4342 | 4716 | 4326 | 4475 | 5977 |
| Total Current Liabilities | 19001 | 26569 | 22491 | 24050 | 22148 | 23670 |
| Accounts Payable | 3596 | 3528 | 3645 | 4144 | 4357 | 4535 |
| Accrued Expenses | 6444 | 6929 | 8535 | 9111 | 9753 | 11186 |
| Notes Payable/Short Term Debt | 1426 | 765 | 4420 | 5020 | 1145 | 802 |
| Current Port. of LT Debt/Capital Leases | 2703 | 2060 | 1373 | 1898 | 2580 | 2799 |
| Other Current Liabilities, Total | 4832 | 13287 | 4518 | 3877 | 4313 | 4348 |
| Total Liabilities | 57957 | 56449 | 53706 | 68287 | 65844 | 64048 |
| Total Long Term Debt | 14661 | 14264 | 20271 | 23590 | 23425 | 20572 |
| Long Term Debt | 14620 | 14221 | 20227 | 22580 | 22538 | 19760 |
| Capital Lease Obligations | 41 | 43 | 44 | 1010 | 887 | 812 |
| Deferred Income Tax | 1934 | 1396 | 1156 | 3810 | 3600 | 3556 |
| Minority Interest | 3839 | 3557 | -688 | 6952 | 6221 | 6287 |
| Other Liabilities, Total | 18522 | 10663 | 10476 | 9885 | 10450 | 9963 |
| Total Equity | 1124 | -68 | 4360 | 11405 | 14587 | 15055 |
| Common Stock | 1342 | 1343 | 1345 | 1346 | 1346 | 1347 |
| Additional Paid-In Capital | 2954 | 3019 | 3091 | 3174 | 3281 | 3301 |
| Retained Earnings (Accumulated Deficit) | -3263 | -4348 | -8 | 6659 | 8884 | 10073 |
| ESOP Debt Guarantee | -286 | -400 | -161 | -135 | -195 | -28 |
| Unrealized Gain (Loss) | 380 | 329 | 140 | 409 | 1302 | 383 |
| Other Equity, Total | -3 | -11 | -47 | -48 | -31 | -21 |
| Total Liabilities & Shareholders’ Equity | 59081 | 56381 | 58066 | 79692 | 80431 | 79103 |
| Total Common Shares Outstanding | 4910.11 | 4957.95 | 4922.93 | 4953.23 | 5029.98 | 5031.81 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 18524 | 17566 | 18254 | 18674 | 28988 |
| Geldmiddelen en kortetermijnbeleggingen | 4817 | 3562 | 3514 | 4335 | 13977 |
| Geldmiddelen & Equivalenten | 4757 | 3503 | 3453 | 4274 | 10967 |
| Korte Termijn Investeringen | 60 | 59 | 61 | 61 | 3010 |
| Totale Vorderingen, Netto | 7183 | 7507 | 8284 | 8346 | 8797 |
| Accounts Receivable - Trade, Net | 6492 | 6902 | 7697 | 7860 | 8300 |
| Total Inventory | 6216 | 6330 | 6244 | 5783 | 6003 |
| Other Current Assets, Total | 308 | 167 | 212 | 210 | 211 |
| Total Assets | 78079 | 77011 | 78689 | 79103 | 89689 |
| Property/Plant/Equipment, Total - Net | 10633 | 10589 | 10667 | 10672 | 10704 |
| Goodwill, Net | 10442 | 10435 | 10582 | 10552 | 10705 |
| Intangibles, Net | 29418 | 29333 | 30241 | 30079 | 30468 |
| Long Term Investments | 3755 | 3235 | 2818 | 2214 | 1739 |
| Other Long Term Assets, Total | 5307 | 5853 | 6127 | 6912 | 7085 |
| Total Current Liabilities | 20275 | 21387 | 22417 | 23670 | 24278 |
| Payable/Accrued | 14610 | 14267 | 15230 | 17554 | 17577 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 3172 | 5041 | 4869 | 3601 | 4102 |
| Other Current Liabilities, Total | 2493 | 2079 | 2318 | 2515 | 2599 |
| Total Liabilities | 63214 | 61634 | 63263 | 64048 | 73508 |
| Total Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
| Long Term Debt | 23047 | 20442 | 20736 | 20572 | 29226 |
| Deferred Income Tax | 3566 | 3587 | 3666 | 3556 | 3668 |
| Minority Interest | 6145 | 6201 | 6322 | 6287 | 6451 |
| Other Liabilities, Total | 10181 | 10017 | 10122 | 9963 | 9885 |
| Total Equity | 14865 | 15377 | 15426 | 15055 | 16181 |
| Common Stock | 1346 | 1347 | 1347 | 1347 | 1347 |
| Additional Paid-In Capital | 3296 | 3299 | 3300 | 3301 | 3436 |
| Retained Earnings (Accumulated Deficit) | 10223 | 10731 | 10779 | 10407 | 11398 |
| Total Liabilities & Shareholders’ Equity | 78079 | 77011 | 78689 | 79103 | 89689 |
| Total Common Shares Outstanding | 5031.39 | 5031.68 | 5031.74 | 5031.81 | 5083.9 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | 1062 | 2169 | 4046 | 5268 | 6388 | 5096 |
| Geldmiddelen uit Operationele Activiteiten | 6497 | 6918 | 8421 | 8020 | 8441 | 7952 |
| Geldmiddelen uit Operationele Activiteiten | 978 | 988 | 954 | 1231 | 1214 | 1195 |
| Amortization | 796 | 934 | 902 | 1103 | 1137 | 1182 |
| Niet-Geldelijke Posten | 1641 | 3072 | 1406 | 2416 | -305 | 1381 |
| Cash Taxes Paid | 1609 | 1340 | 1326 | 1512 | 1655 | 1291 |
| Contant Betaalde Rente | 732 | 781 | 766 | 895 | 864 | 786 |
| Veranderingen in het Operationeel Kapitaal | 2020 | -245 | 1113 | -1998 | 7 | -902 |
| Geldmiddelen uit Investeringsactiviteiten | -1269 | -1443 | -1553 | -5354 | 2161 | -1777 |
| Kapitaaluitgaven | -2352 | -2202 | -1796 | -2163 | -2239 | -2931 |
| Overige Cash Flow investeringsposten, Totaal | 1083 | 759 | 243 | -3191 | 4400 | 1154 |
| Geldmiddelen uit Financieringsactiviteiten | -6392 | -6380 | -6389 | -1840 | -10132 | -7589 |
| Financiering van Cash Flow Posten | -1687 | -1475 | -10660 | -1453 | -1950 | -1401 |
| Total Cash Dividends Paid | -4850 | -3906 | -3927 | -3953 | -3977 | -3999 |
| Uitgifte (Aflossing) van aandelen, netto | 15 | -9 | 74 | 51 | 29 | 21 |
| Uitgifte (Aflossing) van Schulden, Netto | 130 | -990 | 8124 | 3515 | -4234 | -2210 |
| Wisselkoerseffecten | 283 | -100 | 8 | -82 | -39 | -29 |
| Nettowijziging in Geldmiddelen | -881 | -1005 | 487 | 744 | 431 | -1443 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1260 | 2798 | 4166 | 5096 | 2167 |
| Cash From Operating Activities | 331 | 1623 | 4185 | 7952 | 2542 |
| Cash From Operating Activities | 361 | 1025 | 2011 | 2377 | 704 |
| Non-Cash Items | 433 | 570 | 1140 | 1381 | 634 |
| Cash Taxes Paid | 155 | 700 | 857 | 1291 | 213 |
| Cash Interest Paid | 95 | 439 | 486 | 786 | 85 |
| Changes in Working Capital | -1723 | -2770 | -3132 | -902 | -963 |
| Cash From Investing Activities | -48 | -233 | -1416 | -1777 | -3593 |
| Capital Expenditures | -354 | -1015 | -2299 | -2931 | -601 |
| Other Investing Cash Flow Items, Total | 306 | 782 | 883 | 1154 | -2992 |
| Cash From Financing Activities | -1376 | -3421 | -4815 | -7589 | 7973 |
| Financing Cash Flow Items | -391 | -883 | -1052 | -1401 | 16 |
| Total Cash Dividends Paid | -946 | -2097 | -3048 | -3999 | -952 |
| Issuance (Retirement) of Stock, Net | 15 | 19 | 20 | 21 | 12 |
| Issuance (Retirement) of Debt, Net | -54 | -460 | -735 | -2210 | 8897 |
| Foreign Exchange Effects | -35 | -34 | -21 | -29 | 12 |
| Net Change in Cash | -1128 | -2065 | -2067 | -1443 | 6934 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5959 | 229134683 | -34164923 | 2022-07-19 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.1513 | 129037070 | 1316706 | 2022-11-29 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3261 | 95245653 | 977516 | 2023-01-01 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 1.9416 | 79502299 | 0 | 2022-02-27 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.2735 | 52145714 | 113556 | 2023-01-01 | LOW |
| Silchester International Investors, L.L.P. | Investment Advisor/Hedge Fund | 1.2688 | 51954188 | 12827890 | 2022-11-28 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.2106 | 49570121 | -418206 | 2023-01-01 | LOW |
| Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.9197 | 37659407 | -1831852 | 2022-11-28 | LOW |
| Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.8804 | 36048753 | 1255452 | 2023-01-01 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.8357 | 34220716 | -131359 | 2023-01-01 | LOW |
| Franklin Mutual Advisers, LLC | Investment Advisor/Hedge Fund | 0.7629 | 31239940 | 2050203 | 2023-01-01 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5453 | 22328352 | 526606 | 2022-11-29 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5138 | 21037527 | -869474 | 2022-11-28 | LOW |
| Jupiter Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.4996 | 20457122 | 1270578 | 2022-11-28 | LOW |
| Independent Franchise Partners LLP | Investment Advisor | 0.4732 | 19376797 | 6500373 | 2022-11-29 | LOW |
| Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.4639 | 18995200 | -674014 | 2023-01-01 | LOW |
| GlaxoSmithKline Plc ESOP | Corporation | 0.4534 | 18564231 | -20616012 | 2021-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 0.4354 | 17828669 | -58801534 | 2022-11-29 | LOW |
| Mondrian Investment Partners Ltd. | Investment Advisor | 0.4144 | 16967070 | -246648 | 2022-11-29 | LOW |
| Schweizerische Nationalbank | Bank and Trust | 0.4129 | 16908425 | -1156909 | 2022-11-28 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group +485000+
Handelaren
65000+
Actieve klanten per maand
$48000000+
Maandelijks beleggingsvolume
$28000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelscommissie
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Hefboom
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
GSK Company profile
Over GlaxoSmithKline PLC
GlaxoSmithKline PLC is een wereldwijd bedrijf in de gezondheidszorg. Het bedrijf onderzoekt en ontwikkelt een reeks producten in drie primaire domeinen: Farmaceutische Producten, Vaccins en Consumentengezondheidszorg. De productformuleringen omvatten tabletten, crèmes/zalven, inhalatoren, injecties, vloeistoffen en steriele producten. De farmaceutische tak heeft een portefeuille van gevestigde geneesmiddelen voor de luchtwegen, het humaan immunodeficiëntievirus (HIV), immuno-inflammatie en oncologie. De divisie Vaccins heeft een portefeuille met vaccins die mensen gedurende hun hele leven tegen een reeks ziekten moeten beschermen. De vaccins pakken ziekten aan zoals pneumokokkenziekte, meningitis, hepatitis, rotavirus, kinkhoest en griep. De divisie Consumer Healthcare combineert wetenschappelijke inzichten met consumenteninzichten om alledaagse gezondheidsmerken te creëren die consumenten vertrouwen en die deskundigen aanbevelen voor mondhygiëne, pijnbestrijding, verkoudheid, griep en allergie, gezondheid van de spijsvertering en vitaminen, mineralen en supplementen.
| Industry: | Pharmaceuticals (NEC) |
980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen